{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:45:20Z","timestamp":1780087520512,"version":"3.54.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgrounds<\/jats:title>\n                <jats:p>It has been observed that high levels of enhancer of zeste homolog 2 (EZH2) expression are associated with unsatisfactory prognoses and can be found in a wide range of malignancies. However, the effects of EZH2 on Lung Adenocarcinoma (LUAD) remain elusive. Through the integration of bioinformatic analyses, the present paper sought to ascertain the effects of EZH2 in LUAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The TIMER and UALCAN databases were applied to analyze mRNA and protein expression data for EZH2 in LUAD. The result of immunohistochemistry was obtained from the HPA database, and the survival curve was drawn according to the library provided by the HPA database. The LinkedOmics database was utilized to investigate the co-expressed genes and signal transduction pathways with EZH2. Up- and down-regulated genes from The Linked Omics database were introduced to the CMap database to predict potential drug targets for LUAD using the CMap database. The association between EZH2 and cancer-infiltrating immunocytes was studied through TIMER and TISIDB. In addition, this paper explores the relationship between EZH2 mRNA expression and NSCLC OS using the Kaplan\u2013Meier plotter database to further validate and complement the research. Furthermore, the correlation between EZH2 expression and EGFR genes, KRAS genes, BRAF genes, and smoking from the Cancer Genome Atlas (TCGA) database is analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In contrast to paracancer specimens, the mRNA and protein levels of EZH2 were higher in LUAD tissues. Significantly, high levels of EZH2 were associated with unsatisfactory prognoses in LUAD patients. Additionally, the coexpressed genes of EZH2 were predominantly associated with numerous cell growth-associated pathways, including the cell cycle, DNA replication, RNA transport, and the p53 signaling pathway, according to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways. The results of TCGA database revealed that the expression of EZH2 was lower in normal tissues than in lung cancer tissues (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Smoking was associated with elevated EZH2 expression (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). EZH2 was highly expressed in lung cancers with positive KRAS expression, and the correlation was significant in lung adenocarcinoma (<jats:italic>r<\/jats:italic>\u2009=\u20090.3129, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). CMap was applied to determine the top 15 positively correlated drugs\/molecules and the top 15 negatively correlated drugs\/molecules. MK-1775, MK-5108, fenbendazole, albendazole, BAY-K8644, evodiamine, purvalanol-a, mycophenolic-acid, PHA-793887, and cyclopamine are potential drugs for patients with lung adenocarcinoma and high EZH2 expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Highly expressed EZH2 is a predictor of a suboptimal prognosis in LUAD and may serve as a prognostic marker and target gene for LUAD. The underlying cause may be associated with the synergistic effect of KRAS, immune cell infiltration, and metabolic processes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-023-05271-7","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T14:02:38Z","timestamp":1681740158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates"],"prefix":"10.1186","volume":"24","author":[{"given":"Kui","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-chuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"5271_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00214","volume":"4","author":"VC Cordeiro de Lima","year":"2018","unstructured":"Cordeiro de Lima VC, Baldotto CS, Barrios CH, Sobrinho EM, Zukin M, Mathias C, et al. Stage III non-small-cell lung cancer treated with concurrent chemoradiation followed or not by consolidation chemotherapy: a survival analysis from. J Glob Oncol. 2018;4:1\u201311. https:\/\/doi.org\/10.1200\/JGO.17.00214.","journal-title":"J Glob Oncol"},{"key":"5271_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2147\/CMAR.S187317","volume":"11","author":"T Lu","year":"2019","unstructured":"Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943\u201353. https:\/\/doi.org\/10.2147\/CMAR.S187317.","journal-title":"Cancer Manag Res"},{"key":"5271_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345\u201356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2.","journal-title":"Nat Med"},{"key":"5271_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009.","journal-title":"J Thorac Oncol"},{"key":"5271_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243\u201360. https:\/\/doi.org\/10.1097\/JTO.0000000000000630.","journal-title":"J Thorac Oncol"},{"key":"5271_CR6","unstructured":"Clark SB, Alsubait S. StatPearls: Non Small Cell Lung Cancer. 2022."},{"key":"5271_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:504\u201335. https:\/\/doi.org\/10.6004\/jnccn.2017.0050.","journal-title":"J Natl Compr Cancer Netw."},{"key":"5271_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103\u20139. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.019.","journal-title":"Semin Cancer Biol"},{"key":"5271_CR9","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12:2540. https:\/\/doi.org\/10.1038\/s41467-021-22801-0.","journal-title":"Nat Commun"},{"key":"5271_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrg3173","volume":"13","author":"EL Greer","year":"2012","unstructured":"Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343\u201357. https:\/\/doi.org\/10.1038\/nrg3173.","journal-title":"Nat Rev Genet"},{"key":"5271_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469:343\u20139. https:\/\/doi.org\/10.1038\/nature09784.","journal-title":"Nature"},{"key":"5271_CR12","doi-asserted-by":"publisher","first-page":"2380124","DOI":"10.1155\/2020\/2380124","volume":"2020","author":"K Fan","year":"2020","unstructured":"Fan K, Zhang C-L, Qi Y-F, Dai X, Birling Y, Tan Z-F, Cao F. Prognostic value of EZH2 in non-small-cell lung cancers: a meta-analysis and bioinformatics analysis. Biomed Res Int. 2020;2020:2380124. https:\/\/doi.org\/10.1155\/2020\/2380124.","journal-title":"Biomed Res Int"},{"key":"5271_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22:128\u201334. https:\/\/doi.org\/10.1038\/nm.4036.","journal-title":"Nat Med"},{"key":"5271_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jb\/mvab007","volume":"170","author":"S Hanaki","year":"2021","unstructured":"Hanaki S, Shimada M. Targeting EZH2 as cancer therapy. J Biochem. 2021;170:1\u20134. https:\/\/doi.org\/10.1093\/jb\/mvab007.","journal-title":"J Biochem"},{"key":"5271_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10. https:\/\/doi.org\/10.1186\/s40364-018-0122-2.","journal-title":"Biomark Res"},{"key":"5271_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.omtn.2021.12.032","volume":"27","author":"F-F Hu","year":"2022","unstructured":"Hu F-F, Chen H, Duan Y, Lan B, Liu C-J, Hu H, et al. CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma. Mol Ther Nucleic Acids. 2022;27:670\u201384. https:\/\/doi.org\/10.1016\/j.omtn.2021.12.032.","journal-title":"Mol Ther Nucleic Acids"},{"key":"5271_CR17","doi-asserted-by":"publisher","first-page":"e932275","DOI":"10.12659\/MSM.932275","volume":"27","author":"C Gao","year":"2021","unstructured":"Gao C, Gu X, Chen Y, Zhou M, Jiang F, Zheng S. Identification of potential prognostic and predictive biomarkers for immune-checkpoint inhibitor response in small cell lung cancer. Med Sci Monit. 2021;27:e932275. https:\/\/doi.org\/10.12659\/MSM.932275.","journal-title":"Med Sci Monit"},{"key":"5271_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher P, Warren S, Dennis L, D\u2019Amico L, White A, Disis ML, et al. Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer. 2017;5:18. https:\/\/doi.org\/10.1186\/s40425-017-0215-8.","journal-title":"J Immunother Cancer"},{"key":"5271_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbo.2016.03.004","volume":"5","author":"S Sousa","year":"2016","unstructured":"Sousa S, M\u00e4\u00e4tt\u00e4 J. The role of tumour-associated macrophages in bone metastasis. J Bone Oncol. 2016;5:135\u20138. https:\/\/doi.org\/10.1016\/j.jbo.2016.03.004.","journal-title":"J Bone Oncol"},{"key":"5271_CR20","doi-asserted-by":"publisher","first-page":"e0179726","DOI":"10.1371\/journal.pone.0179726","volume":"12","author":"NO Siemers","year":"2017","unstructured":"Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, Szustakowski JD. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS ONE. 2017;12:e0179726. https:\/\/doi.org\/10.1371\/journal.pone.0179726.","journal-title":"PLoS ONE"},{"key":"5271_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649\u201358. https:\/\/doi.org\/10.1016\/j.neo.2017.05.002.","journal-title":"Neoplasia"},{"key":"5271_CR22","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956\u201363. https:\/\/doi.org\/10.1093\/nar\/gkx1090.","journal-title":"Nucleic Acids Res"},{"key":"5271_CR23","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587\u201392. https:\/\/doi.org\/10.1093\/nar\/gkac963.","journal-title":"Nucleic Acids Res"},{"key":"5271_CR24","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Prot Sci Publ Prot Soc. 2019;28:1947\u201351. https:\/\/doi.org\/10.1002\/pro.3715.","journal-title":"Prot Sci Publ Prot Soc"},{"key":"5271_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27.","journal-title":"Nucleic Acids Res"},{"key":"5271_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12957-021-02479-w","volume":"20","author":"W Mu","year":"2022","unstructured":"Mu W, Xie Y, Li J, Yan R, Zhang J, Liu Y, Fan Y. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. World J Surg Oncol. 2022;20:22. https:\/\/doi.org\/10.1186\/s12957-021-02479-w.","journal-title":"World J Surg Oncol"},{"key":"5271_CR27","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437-1452.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049.","journal-title":"Cell"},{"key":"5271_CR28","first-page":"95","volume":"10","author":"C-Y Wang","year":"2020","unstructured":"Wang C-Y, Chiao C-C, Phan NN, Li C-Y, Sun Z-D, Jiang J-Z, et al. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. Am J Cancer Res. 2020;10:95\u2013113.","journal-title":"Am J Cancer Res"},{"key":"5271_CR29","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35:4200\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210.","journal-title":"Bioinformatics"},{"key":"5271_CR30","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24:69\u201371.","journal-title":"Malawi Med J"},{"key":"5271_CR31","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A L\u00e1nczky","year":"2021","unstructured":"L\u00e1nczky A, Gy\u0151rffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23:e27633. https:\/\/doi.org\/10.2196\/27633.","journal-title":"J Med Internet Res"},{"key":"5271_CR32","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.18632\/aging.203345","volume":"13","author":"T-J Kao","year":"2021","unstructured":"Kao T-J, Wu C-C, Phan NN, Liu Y-H, Ta HDK, Anuraga G, et al. Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer. Aging. 2021;13:17970. https:\/\/doi.org\/10.18632\/aging.203345.","journal-title":"Aging"},{"key":"5271_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40246-017-0123-5","volume":"11","author":"D Monies","year":"2017","unstructured":"Monies D, Abou Al-Shaar H, Goljan EA, Al-Younes B, Al-Breacan MMA, Al-Saif MM, et al. Identification of a novel genetic locus underlying tremor and dystonia. Hum Genom. 2017;11:25. https:\/\/doi.org\/10.1186\/s40246-017-0123-5.","journal-title":"Hum Genom"},{"key":"5271_CR34","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","volume":"17","author":"KA Bridges","year":"2011","unstructured":"Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011;17:5638\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0650.","journal-title":"Clin Cancer Res"},{"key":"5271_CR35","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1038\/onc.2017.297","volume":"36","author":"G Chen","year":"2017","unstructured":"Chen G, Zhang B, Xu H, Sun Y, Shi Y, Luo Y, et al. Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. Oncogene. 2017;36:6863\u201372. https:\/\/doi.org\/10.1038\/onc.2017.297.","journal-title":"Oncogene"},{"key":"5271_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00432-014-1675-6","volume":"140","author":"DC Chinn","year":"2014","unstructured":"Chinn DC, Holland WS, Mack PC. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol. 2014;140:1137\u201349. https:\/\/doi.org\/10.1007\/s00432-014-1675-6.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5271_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2019.03.002","volume":"451","author":"I Shimomura","year":"2019","unstructured":"Shimomura I, Yokoi A, Kohama I, Kumazaki M, Tada Y, Tatsumi K, et al. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. Cancer Lett. 2019;451:11\u201322. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.002.","journal-title":"Cancer Lett"},{"key":"5271_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061201","author":"M Studenovsk\u00fd","year":"2022","unstructured":"Studenovsk\u00fd M, Rumlerov\u00e1 A, Kov\u00e1\u0159ov\u00e1 J, Dvo\u0159\u00e1kov\u00e1 B, Siv\u00e1k L, Kostka L, et al. HPMA copolymer mebendazole conjugate allows systemic administration and possesses antitumour activity in vivo. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14061201.","journal-title":"Pharmaceutics"},{"key":"5271_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003819","author":"L Zhu","year":"2022","unstructured":"Zhu L, Kuang X, Zhang G, Liang L, Liu D, Hu B, et al. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003819.","journal-title":"J Immunother Cancer"},{"key":"5271_CR40","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1039\/c9md00108e","volume":"10","author":"E Gonz\u00e1lez-Hern\u00e1ndez","year":"2019","unstructured":"Gonz\u00e1lez-Hern\u00e1ndez E, Aparicio R, Garayoa M, Montero MJ, Sevilla M\u00c1, P\u00e9rez-Melero C. Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents. Medchemcomm. 2019;10:1589\u201398. https:\/\/doi.org\/10.1039\/c9md00108e.","journal-title":"Medchemcomm"},{"key":"5271_CR41","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.7150\/thno.49876","volume":"11","author":"SY Hyun","year":"2021","unstructured":"Hyun SY, Le HT, Min H-Y, Pei H, Lim Y, Song I, et al. Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70. Theranostics. 2021;11:2932\u201352. https:\/\/doi.org\/10.7150\/thno.49876.","journal-title":"Theranostics"},{"key":"5271_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/ijmm.2017.2989","volume":"40","author":"X Chen","year":"2017","unstructured":"Chen X, Liao Y, Long D, Yu T, Shen F, Lin X. The Cdc2\/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18\/stathmin in non-small cell lung cancer cells in vitro. Int J Mol Med. 2017;40:235\u201342. https:\/\/doi.org\/10.3892\/ijmm.2017.2989.","journal-title":"Int J Mol Med"},{"key":"5271_CR43","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1158\/0008-5472.CAN-21-0980","volume":"81","author":"X Chen","year":"2021","unstructured":"Chen X, Zhao Y, Wang D, Lin Y, Hou J, Xu X, et al. The HNF4\u03b1-BC200-FMR1-positive feedback loop promotes growth and metastasis in invasive mucinous lung adenocarcinoma. Cancer Res. 2021;81:5904\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0980.","journal-title":"Cancer Res"},{"key":"5271_CR44","doi-asserted-by":"publisher","first-page":"117793222210887","DOI":"10.1177\/11779322221088796","volume":"16","author":"\u00d6C Erkin","year":"2022","unstructured":"Erkin \u00d6C, C\u00f6mertpay B, G\u00f6v E. Integrative analysis for identification of therapeutic targets and prognostic signatures in non-small cell lung cancer. Bioinform Biol Insights. 2022;16:11779322221088796. https:\/\/doi.org\/10.1177\/11779322221088796.","journal-title":"Bioinform Biol Insights"},{"key":"5271_CR45","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41598-018-38345-1","volume":"9","author":"SP Kalainayakan","year":"2019","unstructured":"Kalainayakan SP, Ghosh P, Dey S, Fitzgerald KE, Sohoni S, Konduri PC, et al. Cyclopamine tartrate, a modulator of hedgehog signaling and mitochondrial respiration, effectively arrests lung tumor growth and progression. Sci Rep. 2019;9:1405. https:\/\/doi.org\/10.1038\/s41598-018-38345-1.","journal-title":"Sci Rep"},{"key":"5271_CR46","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-19-2925","volume":"27","author":"J Sun","year":"2021","unstructured":"Sun J, Lu Q, Sanmamed MF, Wang J. Siglec-15 as an emerging target for next-generation cancer immunotherapy. Clin Cancer Res. 2021;27:680\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2925.","journal-title":"Clin Cancer Res"},{"key":"5271_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-021-01161-8","volume":"14","author":"W Qian","year":"2021","unstructured":"Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14:147. https:\/\/doi.org\/10.1186\/s13045-021-01161-8.","journal-title":"J Hematol Oncol"},{"key":"5271_CR48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683\u201392. https:\/\/doi.org\/10.1016\/j.cell.2007.01.029.","journal-title":"Cell"},{"key":"5271_CR49","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/carcin\/bgq147","volume":"31","author":"LL Kodach","year":"2010","unstructured":"Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJM, Langers AMJ, Verspaget HW, et al. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis. 2010;31:1567\u201375. https:\/\/doi.org\/10.1093\/carcin\/bgq147.","journal-title":"Carcinogenesis"},{"key":"5271_CR50","doi-asserted-by":"publisher","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100:11606\u201311. https:\/\/doi.org\/10.1073\/pnas.1933744100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5271_CR51","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-19-2415","volume":"80","author":"S Hoxha","year":"2020","unstructured":"Hoxha S, Shepard A, Troutman S, Diao H, Doherty JR, Janiszewska M, et al. YAP-mediated recruitment of YY1 and EZH2 represses transcription of key cell-cycle regulators. Cancer Res. 2020;80:2512\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2415.","journal-title":"Cancer Res"},{"key":"5271_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","volume":"23","author":"A Kong","year":"2021","unstructured":"Kong A, Mehanna H. WEE1 inhibitor: clinical development. Curr Oncol Rep. 2021;23:107. https:\/\/doi.org\/10.1007\/s11912-021-01098-8.","journal-title":"Curr Oncol Rep"},{"key":"5271_CR53","doi-asserted-by":"publisher","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","volume":"10","author":"D-H Ha","year":"2020","unstructured":"Ha D-H, Min A, Kim S, Jang H, Kim SH, Kim H-J, et al. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Sci Rep. 2020;10:9930. https:\/\/doi.org\/10.1038\/s41598-020-66018-5.","journal-title":"Sci Rep"},{"key":"5271_CR54","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1172\/JCI122622","volume":"129","author":"AB Bukhari","year":"2019","unstructured":"Bukhari AB, Lewis CW, Pearce JJ, Luong D, Chan GK, Gamper AM. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. J Clin Investig. 2019;129:1329\u201344. https:\/\/doi.org\/10.1172\/JCI122622.","journal-title":"J Clin Investig"},{"key":"5271_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12070652","author":"Y Li","year":"2022","unstructured":"Li Y, Elakad O, Yao S, von Hammerstein-Equord A, Hinterthaner M, Danner BC, et al. Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS-mutated human pulmonary adenocarcinoma. Metabolites. 2022. https:\/\/doi.org\/10.3390\/metabo12070652.","journal-title":"Metabolites"},{"key":"5271_CR56","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1186\/s12885-020-07531-8","volume":"20","author":"A Biswas","year":"2020","unstructured":"Biswas A, Mukherjee G, Kondaiah P, Desai KV. Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer. BMC Cancer. 2020;20:1159. https:\/\/doi.org\/10.1186\/s12885-020-07531-8.","journal-title":"BMC Cancer"},{"key":"5271_CR57","doi-asserted-by":"publisher","first-page":"15988","DOI":"10.1073\/pnas.1521740112","volume":"112","author":"J Yin","year":"2015","unstructured":"Yin J, Leavenworth JW, Li Y, Luo Q, Xie H, Liu X, et al. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci USA. 2015;112:15988\u201393. https:\/\/doi.org\/10.1073\/pnas.1521740112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5271_CR58","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.molcel.2021.03.037","volume":"81","author":"X Dai","year":"2021","unstructured":"Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81:2317-2331.e6. https:\/\/doi.org\/10.1016\/j.molcel.2021.03.037.","journal-title":"Mol Cell"},{"key":"5271_CR59","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","volume":"79","author":"S Huang","year":"2019","unstructured":"Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 2019;79:2009\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2395.","journal-title":"Cancer Res"},{"key":"5271_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610109","author":"C-L Zhang","year":"2022","unstructured":"Zhang C-L, Fan K, Gao M-Q, Pang B. Prognostic value of glasgow prognostic score in non-small cell lung cancer: a systematic review and meta-analysis. Pathol Oncol Res. 2022. https:\/\/doi.org\/10.3389\/pore.2022.1610109.","journal-title":"Pathol Oncol Res"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-023-05271-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-023-05271-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-023-05271-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T14:02:56Z","timestamp":1681740176000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-023-05271-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5271"],"URL":"https:\/\/doi.org\/10.1186\/s12859-023-05271-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The data for this study come from the online repositories and do not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}